Research programme: anorectants - Abbott/Amgen
Alternative Names: Anorectants research programme - Abbott/Amgen; Antiobesity agents research programme - Abbott/Amgen; Research programme: antiobesity agents - Abbott/AmgenLatest Information Update: 11 Dec 2001
At a glance
- Originator Abbott GmbH & Co. KG; Tularik
- Developer Tularik
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 11 Dec 2001 Discontinued-Preclinical for Obesity in USA (Unknown route)
- 18 Jun 2001 Knoll notified Tularik that it is terminating the collaboration in obesity from October 31, 2001
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories